Inactive Instrument

Alcon Stock Borsa Italiana

Stocks

CH0432492467

Medical Equipment, Supplies & Distribution

Real-time Estimate Tradegate 02:24:56 2026-07-16 am EDT 5-day change 1st Jan Change
59.81 EUR +15.02% Intraday chart for Alcon 0.00% -

Valuation: Alcon

Market Cap 33.48B 29.27B 27B 24.82B 47.03B 3,221B 47.83B 322B 126B 1,574B 126B 123B 5,426B P/E 2026 *
31.4x
P/E 2027 * 24.7x
Enterprise Value 36.07B 31.54B 29.09B 26.74B 50.67B 3,471B 51.54B 347B 136B 1,696B 135B 132B 5,847B EV / Sales 2026 *
3.24x
EV / Sales 2027 * 2.96x
Free-Float
97.36%
Yield 2026 *
0.51%
Yield 2027 * 0.59%
Manager TitleAgeSince
Chief Executive Officer 60 2018-06-30
Director of Finance/CFO 58 2019-04-07
Chief Tech/Sci/R&D Officer - 2024-12-31
Director TitleAgeSince
Director/Board Member 60 -
Chairman 70 2018-06-30
Director/Board Member 63 2019-01-31
Change 5-day change 1-year change 3-year change Capi.($)
+15.02%0.00% - - 33.48B
+1.85%-0.68%-30.55%-4.49% 88.44B
+3.05%+1.42%-2.22%-28.93% 13.77B
-1.30%-1.61% - - 9.84B
+6.38%-1.28%-31.66%+509.45% 1.81B
+3.14%+4.69%-28.00%-64.99% 1.48B
+2.10%-2.67%+24.15%-1.35% 871M
+2.63%+3.32%-35.93%-24.73% 868M
+2.50%+4.18%+50.70%-30.20% 769M
+3.05%+0.68% - - 689M
Average +2.31%-0.96%-7.64%+50.68% 13.17B
Weighted average by Cap. +1.42%-1.02%-25.95%-0.15%

Financials

2026 *2027 *
Net sales 11.14B 9.74B 8.98B 8.26B 15.65B 1,072B 15.91B 107B 42.08B 524B 41.83B 40.91B 1,805B 11.82B 10.33B 9.53B 8.76B 16.6B 1,137B 16.88B 114B 44.64B 556B 44.37B 43.4B 1,915B
Net income 1.11B 973M 898M 825M 1.56B 107B 1.59B 10.72B 4.21B 52.36B 4.18B 4.09B 180B 1.38B 1.21B 1.11B 1.02B 1.94B 133B 1.97B 13.28B 5.21B 64.85B 5.18B 5.06B 224B
Net Debt 2.6B 2.27B 2.09B 1.92B 3.65B 250B 3.71B 24.99B 9.81B 122B 9.75B 9.53B 421B 1.54B 1.35B 1.24B 1.14B 2.16B 148B 2.2B 14.84B 5.82B 72.47B 5.79B 5.66B 250B
Logo Alcon
Alcon Inc. is the global leader in the design, manufacture and marketing of ophthalmic care products. Net sales break down by category of products as follows: - ophthalmic surgical products and equipment (55.7%): consumables (52.7% of net sales), implantable products (31%) and other products (16.3%; in particular surgical equipment) for the treatment of cataracts, retinal diseases, glaucoma and refractive errors; - vision care products (44.3%): contact lenses (60.6% of sales) and eye care products (39.4%; eye drops and ophthalmic ointments, etc.). At the end of 2025, the group operated 17 production sites worldwide. Net sales are distributed geographically as follows: Switzerland (0.7%), the United States (45.1%), Japan (5.9%), China (5.5%), and Other (42.8%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
AAA